신경 유전학적 검사 시장 - 전략적 인사이트와 예측(2026-2035년)

The Neurogenetic Testing Market is predicted to increase at a CAGR of 11.6% from a market size of USD 5.41 billion in 2026 to USD 14.58 billion in 2035.

The global neurogenetic testing market is experiencing rapid expansion, driven by advances in genomic sequencing technologies and the growing recognition of genetic diagnosis in precision neurology. This market functions as a critical component of precision neurology by connecting genomic sequencing technologies with clinical diagnosis and long-term disease management. Genetic testing identifies inherited or de novo variants responsible for numerous neurological disorders, allowing physicians to establish definitive diagnoses, estimate disease progression, evaluate familial risk, and identify patients eligible for targeted therapies or clinical trials. Demand continues to increase because rare neurological diseases often remain undiagnosed for years when molecular testing is unavailable or delayed. Healthcare systems are recognizing that earlier genetic diagnosis reduces unnecessary imaging studies, invasive procedures, and repeated specialist consultations. Diagnostic laboratories are expanding comprehensive gene panels and sequencing capabilities to improve turnaround time and increase diagnostic yield. The strategic importance of neurogenetic testing is increasing alongside advances in gene therapies, RNA-based therapeutics, and personalized medicine, making molecular diagnosis an essential prerequisite for therapy selection. This relationship between diagnostics and therapeutics is strengthening long-term demand for comprehensive neurogenetic testing across developed and emerging healthcare markets.

Market Drivers

Increasing Adoption of Next-Generation Sequencing in Neurology

• Next-generation sequencing serves as the technological foundation of modern neurogenetic diagnostics because it analyzes multiple genes simultaneously with high analytical sensitivity. Healthcare providers are replacing sequential diagnostic workflows with comprehensive sequencing strategies to shorten diagnostic timelines. This transition reduces repeated testing while improving identification of pathogenic variants across genetically complex disorders. The result is greater clinical confidence and expanding demand for comprehensive neurogenetic testing services.

Rising Burden of Rare and Inherited Neurological Disorders

• Rare neurological diseases collectively affect millions of individuals worldwide despite the low prevalence of individual conditions. Diagnostic uncertainty frequently delays treatment decisions and increases healthcare costs. Hospitals are expanding access to genetic testing because molecular diagnosis provides definitive disease classification and informs long-term patient management. Improved clinical awareness therefore continues to strengthen testing volumes across pediatric and adult neurology.

Expansion of Precision Medicine

• Precision medicine depends on accurate molecular characterization before targeted therapies can be prescribed. Pharmaceutical companies are developing gene therapies and mutation-specific treatments that require validated genetic diagnoses before patient enrollment or treatment initiation. This therapeutic evolution is increasing collaboration between diagnostic laboratories, clinicians, and biotechnology companies while reinforcing sustained market demand.

Growing Clinical Integration of Genomic Medicine

• Healthcare institutions increasingly recognize genomic testing as part of routine neurological evaluation for selected patient populations. Clinical guidelines are supporting broader genetic evaluation for inherited neurological disorders, encouraging earlier referrals to genetic specialists. This integration strengthens laboratory utilization while improving multidisciplinary management of complex neurological diseases.

Market Restraints

• High costs associated with comprehensive sequencing and advanced bioinformatics remain a barrier in healthcare systems with limited reimbursement. Interpretation of variants of uncertain significance continues to create clinical complexity and requires specialized genetic expertise. Limited availability of trained clinical geneticists and genetic counselors restricts testing capacity in several regions. Additionally, data privacy concerns regarding genomic information can influence patient and provider acceptance.

Technology and Segment Insights

By Test Type

• Single-gene testing remains clinically relevant for neurological disorders with well-established monogenic causes and characteristic phenotypes. Gene panel testing is increasingly utilized for disorders with significant genetic heterogeneity, offering a balanced approach between cost and comprehensiveness. Whole exome sequencing (WES) and whole genome sequencing (WGS) provide the broadest genomic coverage, improving diagnostic yield for complex or atypical presentations. Chromosomal microarray analysis (CMA) detects copy number variations. Repeat expansion testing is essential for disorders involving nucleotide repeat expansions. Mitochondrial DNA testing identifies variants in the mitochondrial genome.

By Technology

• Next-generation sequencing serves as the dominant technology platform because it combines high analytical throughput with broad genomic coverage. Clinical laboratories are expanding NGS capacity to accommodate growing testing demand while improving workflow automation. Sanger sequencing remains important for targeted variant confirmation and familial segregation analysis. PCR-based testing provides rapid, cost-effective analysis for specific mutations. Microarray-based testing enables high-throughput copy number analysis. Long-read sequencing is emerging as a valuable tool for resolving complex genomic regions and repeat expansions.

By Disease Indication

• Epilepsy represents a major disease indication because numerous inherited epileptic syndromes demonstrate identifiable molecular causes. Neurologists are requesting comprehensive gene panels and exome sequencing earlier in the diagnostic pathway to support treatment selection and prognosis. Neuromuscular disorders, movement disorders, neurodevelopmental disorders, hereditary ataxias, hereditary neuropathies, and leukodystrophies are additional indications driving demand for neurogenetic testing. Earlier molecular confirmation reduces unnecessary investigations while facilitating access to precision therapies and clinical research.

By End User

• Hospitals represent a significant end-user segment, integrating genetic testing into neurology departments and multidisciplinary clinics. Diagnostic laboratories are the primary service providers, offering comprehensive testing panels and interpretation. Specialty neurology clinics are increasingly utilizing genetic testing for targeted patient populations. Academic and research institutes contribute to test development and clinical validation. Reference laboratories provide specialized testing services for complex cases.

Competitive and Strategic Outlook

• The competitive landscape features major diagnostic companies and specialized genomic testing providers. F. Hoffmann-La Roche Ltd. maintains a strong strategic position through its integrated diagnostics portfolio and expertise in molecular medicine, combining advanced sequencing technologies with digital healthcare solutions. Illumina, Inc. is a global leader in next-generation sequencing technologies, providing instruments, reagents, and bioinformatics that form the foundation of many neurogenetic testing workflows. Revvity, Inc. leverages its expertise in genomics and molecular diagnostics to support genetic testing for rare diseases. Quest Diagnostics Incorporated and Labcorp Holdings Inc. operate large diagnostic laboratory networks providing broad access to neurogenetic testing services. Eurofins Scientific SE offers a broad portfolio of molecular diagnostic services. Invitae Corporation and GeneDx Holdings Corp. focus on comprehensive genetic testing for rare inherited diseases, with expertise in exome and genome sequencing.
• Strategic developments include increasing integration of artificial intelligence for variant interpretation, expansion of long-read sequencing capabilities, and development of comprehensive genomic databases. Companies are forming partnerships with healthcare providers, academic institutions, and pharmaceutical developers to improve testing workflows and support therapeutic development. Product launches focus on expanded gene panels, advanced bioinformatics platforms, and automated laboratory workflows. Companies that successfully combine advanced sequencing technologies, robust bioinformatics, and clinical expertise are expected to maintain competitive leadership.

Conclusion

• The neurogenetic testing market is poised for substantial growth, driven by advances in sequencing technologies, the expansion of precision medicine, and increasing clinical integration of genomic testing. The evolution from a specialized diagnostic service toward a core component of neurological practice is reshaping the market. Companies that successfully deliver comprehensive, clinically validated, and interpretable genomic testing solutions are expected to lead the market. Ongoing technological innovation, regulatory support, and expanding healthcare infrastructure across emerging economies will further accelerate adoption throughout the forecast period.

Key Benefits of this Report

• Insightful Analysis: Detailed market insights across regions, customer segments, policies, socio-economic factors, consumer preferences, and industry verticals.
• Competitive Landscape: Understand strategic moves by key players to identify optimal market entry approaches.
• Market Drivers and Future Trends: Assess major growth forces and emerging developments shaping the market.
• Actionable Recommendations: Support strategic decisions to unlock new revenue streams.
• Caters to a Wide Audience: Suitable for startups, research institutions, consultants, SMEs, and large enterprises.

What Businesses Use Our Reports For

• Industry and market insights, opportunity assessment, product demand forecasting, market entry strategy, geographical expansion, capital investment decisions, regulatory analysis, new product development, and competitive intelligence.

Report Coverage

• Historical data from 2021 to 2024, Base year 2025, and Forecast years from 2026 to 2035
• Growth opportunities, challenges, supply chain outlook, regulatory framework, and trend analysis
• Competitive positioning, strategies, and market share evaluation, and trade analysis
• Revenue growth and forecast assessment across segments and regions
• Company profiling including strategies, products, financials, and key developments

TABLE OF CONTENTS

1. Executive Summary

• 1.1 Market Snapshot
• 1.2 Key Findings
• 1.3 Analyst Insights
• 1.4 Strategic Recommendations

2. Research Methodology

• 2.1 Research Design
• 2.2 Data Collection Methodology
• 2.3 Market Size Estimation
• 2.4 Forecasting Model
• 2.5 Assumptions & Limitations

3. Neurogenetic Testing Market Overview, Size & Forecast

• 3.1 Market Definition & Scope
• 3.2 Industry Overview
• 3.3 Industry Evolution
• 3.4 Key Market Trends
• 3.5 Historical Market Size Analysis (2021-2025)
• 3.6 Market Forecast (2026-2035)
• 3.7 Neurogenetic Disease Classification
• 3.8 Disease Burden & Unmet Clinical Needs
• 3.9 Epidemiology & Disease Prevalence Analysis
• 3.10 Diagnosed Patient Population Analysis
• 3.11 Genetic Testing Adoption Analysis
• 3.12 Clinical Testing Landscape

4. Market Dynamics

• 4.1 Market Drivers
• 4.2 Market Restraints
• 4.3 Market Opportunities
• 4.4 Market Challenges

5. Industry Landscape

• 5.1 Industry Value Chain Analysis
• 5.2 Pricing Analysis
• 5.3 Reimbursement Landscape

6. Innovation Landscape

• 6.1 Emerging Technologies
• 6.2 Product Innovation
• 6.3 Clinical Trial Analysis
• 6.4 Pipeline Analysis
• 6.5 AI Integration in Neurogenetic Testing
• 6.6 Technology Roadmap

7. Regulatory Landscape

• 7.1 Regulatory Framework
• 7.2 Approval Pathways
• 7.3 Compliance Requirements

8. Neurogenetic Testing Market Landscape Analysis

• 8.1 Analysis by Technology Platform
• 8.2 Analysis by Test Type
• 8.3 Analysis by Sample Type
• 8.4 Analysis by Clinical Application
• 8.5 Analysis by Testing Methodology
• 8.6 Analysis by End User

9. Neurogenetic Testing Market Segment Analysis (2021-2035)

• 9.1 By Test Type
  • 9.1.1 Single-Gene Testing
  • 9.1.2 Gene Panel Testing
  • 9.1.3 Whole Exome Sequencing (WES)
  • 9.1.4 Whole Genome Sequencing (WGS)
  • 9.1.5 Chromosomal Microarray Analysis (CMA)
  • 9.1.6 Repeat Expansion Testing
  • 9.1.7 Mitochondrial DNA Testing
• 9.2 By Technology
  • 9.2.1 Next-Generation Sequencing (NGS)
  • 9.2.2 Sanger Sequencing
  • 9.2.3 PCR-Based Testing
  • 9.2.4 Microarray-Based Testing
  • 9.2.5 Long-Read Sequencing
• 9.3 By Disease Indication
  • 9.3.1 Epilepsy
  • 9.3.2 Neuromuscular Disorders
  • 9.3.3 Movement Disorders
  • 9.3.4 Neurodevelopmental Disorders
  • 9.3.5 Hereditary Ataxias
  • 9.3.6 Hereditary Neuropathies
  • 9.3.7 Leukodystrophies
  • 9.3.8 Other Neurogenetic Disorders
• 9.4 By Sample Type
  • 9.4.1 Blood
  • 9.4.2 Saliva/Buccal Swab
  • 9.4.3 Tissue Samples
  • 9.4.4 Cerebrospinal Fluid (CSF)
  • 9.4.5 Other Sample Types
• 9.5 By End User
  • 9.5.1 Hospitals
  • 9.5.2 Diagnostic Laboratories
  • 9.5.3 Specialty Neurology Clinics
  • 9.5.4 Academic & Research Institutes
  • 9.5.5 Reference Laboratories

10. Neurogenetic Testing Market Geographical Analysis (2021-2035)

• 10.1 North America
• 10.2 Europe
• 10.3 Asia-Pacific
• 10.4 South America
• 10.5 Middle East & Africa

11. Neurogenetic Testing Market Country Analysis (2021-2035)

• 11.1 United States
• 11.2 Canada
• 11.3 Germany
• 11.4 United Kingdom
• 11.5 France
• 11.6 Italy
• 11.7 Spain
• 11.8 Japan
• 11.9 China
• 11.10 India
• 11.11 South Korea
• 11.12 Australia
• 11.13 Brazil
• 11.14 Saudi Arabia
• 11.15 South Africa

12. Competitive Landscape

• 12.1 Market Share Analysis
• 12.2 Strategic Developments
• 12.3 Mergers & Acquisitions, Partnerships & Collaborations
• 12.4 Product Launches

13. Company Profiles

• 13.1 F. Hoffmann-La Roche Ltd.
• 13.2 Illumina, Inc.
• 13.3 Revvity, Inc.
• 13.4 Quest Diagnostics Incorporated
• 13.5 Labcorp Holdings Inc.
• 13.6 Eurofins Scientific SE
• 13.7 Invitae Corporation
• 13.8 Centogene N.V.
• 13.9 GeneDx Holdings Corp.
• 13.10 Blueprint Genetics Oy
• 13.11 Fulgent Genetics, Inc.
• 13.12 Natera, Inc.
• 13.13 Oxford Nanopore Technologies plc
• 13.14 BGI Genomics Co., Ltd.
• 13.15 Macrogen, Inc.

14. Neurogenetic Testing Market Commercial Forecast Analysis

• 14.1 Single-Gene Testing
• 14.2 Gene Panel Testing
• 14.3 Whole Exome Sequencing
• 14.4 Whole Genome Sequencing
• 14.5 Chromosomal Microarray Analysis
• 14.6 Repeat Expansion Testing
• 14.7 Mitochondrial DNA Testing

15. Investment & Funding Analysis

• 15.1 Venture Capital Trends
• 15.2 Government Funding
• 15.3 R&D Investments

16. Future Outlook

• 16.1 Key Growth Opportunities
• 16.2 Future Industry Trends